Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.1
(2.44%)
USD 24.1
(2.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 154.13 Million USD | 2.06% |
| 2022 | 141.36 Million USD | 8.86% |
| 2021 | 129.85 Million USD | -1.91% |
| 2020 | 132.38 Million USD | 0.32% |
| 2019 | 131.96 Million USD | 14.15% |
| 2018 | 115.6 Million USD | 22.55% |
| 2017 | 94.33 Million USD | 6.59% |
| 2016 | 88.49 Million USD | 5.3% |
| 2015 | 84.03 Million USD | 22.15% |
| 2014 | 68.8 Million USD | -0.78% |
| 2013 | 69.34 Million USD | 10.39% |
| 2012 | 62.81 Million USD | 2.0% |
| 2011 | 61.58 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 39.28 Million USD | -0.77% |
| 2024 Q2 | 36.83 Million USD | -6.23% |
| 2023 Q2 | 35.84 Million USD | -11.3% |
| 2023 Q3 | 35.72 Million USD | -0.33% |
| 2023 Q4 | 39.58 Million USD | 10.81% |
| 2023 Q1 | 40.4 Million USD | 21.21% |
| 2023 FY | 144.28 Million USD | 2.06% |
| 2022 Q4 | 33.33 Million USD | -5.52% |
| 2022 Q1 | 34.21 Million USD | 6.97% |
| 2022 Q2 | 38.53 Million USD | 12.63% |
| 2022 Q3 | 35.28 Million USD | -8.44% |
| 2022 FY | 141.36 Million USD | 8.86% |
| 2021 Q1 | 34.64 Million USD | 2.02% |
| 2021 Q4 | 31.98 Million USD | 21.08% |
| 2021 Q3 | 26.41 Million USD | -28.25% |
| 2021 FY | 129.85 Million USD | -1.91% |
| 2021 Q2 | 36.81 Million USD | 6.28% |
| 2020 Q4 | 33.95 Million USD | 2.92% |
| 2020 Q2 | 36.09 Million USD | 23.02% |
| 2020 Q3 | 32.99 Million USD | -8.61% |
| 2020 FY | 132.38 Million USD | 0.32% |
| 2020 Q1 | 29.34 Million USD | -12.73% |
| 2019 Q1 | 34.07 Million USD | 2.81% |
| 2019 Q3 | 32.84 Million USD | 4.56% |
| 2019 FY | 131.96 Million USD | 14.15% |
| 2019 Q4 | 33.62 Million USD | 2.37% |
| 2019 Q2 | 31.41 Million USD | -7.81% |
| 2018 Q2 | 29.01 Million USD | 7.54% |
| 2018 FY | 115.6 Million USD | 22.55% |
| 2018 Q4 | 33.14 Million USD | 24.09% |
| 2018 Q3 | 26.71 Million USD | -7.94% |
| 2018 Q1 | 26.97 Million USD | 21.29% |
| 2017 Q1 | 24.06 Million USD | -1.65% |
| 2017 Q4 | 22.24 Million USD | -5.19% |
| 2017 Q3 | 23.46 Million USD | -4.48% |
| 2017 Q2 | 24.56 Million USD | 2.06% |
| 2017 FY | 94.33 Million USD | 6.59% |
| 2016 FY | 88.49 Million USD | 5.3% |
| 2016 Q4 | 24.47 Million USD | 12.18% |
| 2016 Q3 | 21.81 Million USD | 2.56% |
| 2016 Q2 | 21.27 Million USD | 3.2% |
| 2016 Q1 | 20.61 Million USD | 10.38% |
| 2015 Q1 | 20.54 Million USD | 8.65% |
| 2015 FY | 84.03 Million USD | 22.15% |
| 2015 Q4 | 18.67 Million USD | -12.43% |
| 2015 Q3 | 21.32 Million USD | -9.28% |
| 2015 Q2 | 23.5 Million USD | 14.42% |
| 2014 Q1 | 14.31 Million USD | -13.67% |
| 2014 Q2 | 15.98 Million USD | 11.67% |
| 2014 FY | 68.8 Million USD | -0.78% |
| 2014 Q4 | 18.9 Million USD | -3.52% |
| 2014 Q3 | 19.59 Million USD | 22.59% |
| 2013 FY | 69.34 Million USD | 10.39% |
| 2013 Q1 | 17.2 Million USD | 8.55% |
| 2013 Q2 | 15.5 Million USD | -9.87% |
| 2013 Q3 | 20.04 Million USD | 29.28% |
| 2013 Q4 | 16.57 Million USD | -17.3% |
| 2012 FY | 62.81 Million USD | 2.0% |
| 2012 Q4 | 15.85 Million USD | 0.0% |
| 2011 FY | 61.58 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -1767.641% |
| Alpha Teknova, Inc. | 45.85 Million USD | -236.104% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 21.353% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -243.635% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 3.187% |
| Cosmos Health Inc. | 26.18 Million USD | -488.729% |
| Journey Medical Corporation | 54.59 Million USD | -182.328% |
| Embecta Corp. | 528.4 Million USD | 70.83% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 43.312% |
| Dynavax Technologies Corporation | 219.14 Million USD | 29.666% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 73.876% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 52.774% |
| PainReform Ltd. | 9.58 Million USD | -1508.243% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1074.402% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1074.402% |
| SCYNEXIS, Inc. | 51.84 Million USD | -197.281% |
| Safety Shot Inc | 12.1 Million USD | -1172.815% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -4921.98% |
| Procaps Group, S.A. | 199.47 Million USD | 22.731% |
| Theratechnologies Inc. | 72.75 Million USD | -111.851% |
| Harrow Health, Inc. | 89.97 Million USD | -71.311% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1531.738% |
| Biofrontera Inc. | 39.95 Million USD | -285.73% |
| DURECT Corporation | 43.71 Million USD | -252.588% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 70.864% |
| Cronos Group Inc. | 96.7 Million USD | -59.379% |
| OptiNose, Inc. | 85.1 Million USD | -81.117% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 33.598% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -293.671% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1712.112% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 50.934% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1483.975% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -258.113% |
| Radius Health, Inc. | 265.92 Million USD | 42.039% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1013.531% |
| ProPhase Labs, Inc. | 37.85 Million USD | -307.202% |
| Phibro Animal Health Corporation | 260.29 Million USD | 40.786% |
| Procaps Group S.A. | 187.24 Million USD | 17.683% |
| Alvotech | 285.43 Million USD | 46.001% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1468.794% |
| Viatris Inc. | 5.96 Billion USD | 97.417% |
| Rockwell Medical, Inc. | 15.37 Million USD | -902.563% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -157.577% |
| SIGA Technologies, Inc. | 22.04 Million USD | -599.242% |
| Tilray Brands, Inc. | 251.35 Million USD | 38.679% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -214.315% |
| Shineco, Inc. | 17.94 Million USD | -758.779% |
| PetIQ, Inc. | 192.72 Million USD | 20.024% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -3761.906% |
| Incannex Healthcare Limited | 30.05 Million USD | -412.874% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 90.346% |
| Alimera Sciences, Inc. | 62.64 Million USD | -146.059% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -20114.507% |
| Assertio Holdings, Inc. | 368.58 Million USD | 58.182% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2518.845% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -765.506% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -628.112% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -632.503% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 6.566% |
| Hempacco Co., Inc. | 7.59 Million USD | -1929.027% |
| Talphera, Inc. | 11.99 Million USD | -1185.093% |
| Alvotech | 285.43 Million USD | 46.001% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -9.537% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 55.311% |
| Currenc Group, Inc. | 24 Million USD | -542.169% |
| Kamada Ltd. | 45.42 Million USD | -239.308% |
| Indivior PLC | 911 Million USD | 83.081% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1142.05% |
| Flora Growth Corp. | 10.57 Million USD | -1356.981% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -632.503% |
| Evolus, Inc. | 189.75 Million USD | 18.774% |
| HUTCHMED (China) Limited | 436.23 Million USD | 64.667% |
| Akanda Corp. | 3.48 Million USD | -4324.678% |